CRISPR Therapeutics AG (CRSP) Convertible Debt (2015)
CRISPR Therapeutics AG (CRSP) posted Convertible Debt of $38.3 million for Q4 2015.
CRISPR Therapeutics AG (CRSP) Convertible Debt (2015) Analysis & Trends
CRISPR Therapeutics AG has reported Convertible Debt for 1 years, with the latest figure at $38.3 million in Q4 2015.
- Quarterly Convertible Debt changed N/A year-over-year to $38.3 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $38.3 million (changed N/A YoY) and the FY2015 annual result came in at $38.3 million, changed N/A from the prior year.
- Convertible Debt was little changed at $38.3 million in Q4 2015 per CRSP's latest filing.
- Over five years, Convertible Debt peaked at $38.3 million in Q4 2015 and troughed at $38.3 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 38.34 Mn |